Nils lofgren family

American Egyptologist
When God Looked the Other Way
The Eye of the Poet
Kipling
Frank Lloyd Wright
Shaggy Muses
Johann Wolfgang von Goethe
Notes and Methods
Scottish Mandarin
Thistle and Bamboo
More than 1001 Days and Nights of Hong Kong Internment
Alberto Giacometti—Time Passes Too Soon
An Exile on Planet Earth
Nasser
Dear Queer Self
Mahatma Gandhi
René Magritte
Law Without Values
Piip, Meierovics & Voldemaras: The Baltic States
Big Bosses
Pentecostal Preacher Woman
Professor Baseball
Frida Kahlo
The Secret Lives of Teachers
The Architecture of Vision
J.-K. Huysmans
Once Upon a Life
Simone de Beauvoir
Charles Darwin
The Correspondence of Hannah Arendt and Gershom Scholem
Alfred Russel Wallace
Richard Owen
The Blues Dream of Billy Boy Arnold
Camus and Sartre
A Sinister Assassin
Madumo, a Man Bewitched
King of Kings
Plato
Weather Forecaster to Research Scientist
Book M
War Diary
Coolie Woman
Theodore Roosevelt
William S. Burroughs
Edison
Margery Kempe
Harold Rosenberg
Serving the Reich
John Ruskin
Jean-François Lyotard
Yves Klein
Becoming Historians
Vivian Maier
Off the Beaten Trac

Overview

iOmx Therapeutics focuses on the development of first-in-class cancer immunotherapies addressing novel immune evasion biologies hijacked by cancer cells. By utilizing its iOTargTM high-throughput screening platform, the Company has identified a number of next-generation immune-checkpoints and is advancing a clinical pipeline of drug candidates against these novel targets that have the potential to address cancers that are resistant to current immunotherapies.

iOmx was founded in 2016 based on the work of its scientific founders Philipp Beckhove, MD, and Nisit Khandelwal, PhD, conducted at the German Cancer Research Center.

Management

Apollon Papadimitriou

Apollon is the Chief Executive Officer. Apollon acted as Chief Development Officer at iOmx from 2017 until mid of 2019. He has a long-standing track record in biotherapeutics development and has significantly contributed to the development and launch of many biologics products. Before joining iOmx in 2017, he acted as Global Head Large Molecule Bioanalytical R&D and Pharmaceutical Sciences Site Head

Nils Melzer

Swiss legal scholar and author

Nils Joachim Melzer (born 1970) is a Swiss academic, author, and practitioner in the field of international law. From 2016 until 2022,[1] Melzer was the United Nations Special Rapporteur on Torture and Other Cruel, Inhuman or Degrading Treatment or Punishment. He is a professor of international law at the University of Glasgow. From 2011-2013, he was Swiss Chair of International Humanitarian Law at the Geneva Academy of International Humanitarian Law and Human Rights. Melzer has criticised the governments of the U.S., the U.K., Ecuador and Sweden over their treatment of Julian Assange.

Education and career

Melzer was graduated summa cum laude from the University of Zürich with a Ph.D. degree in law.[2][3]

Melzer served for 12 years with the International Committee of the Red Cross (ICRC) as delegate, deputy head of delegation, and legal adviser in conflict areas. After leaving the ICRC Melzer held academic positions as research director of the Swiss Competence Centre on Human Rights (Unive

Copyright ©mudmind.pages.dev 2025